Chondroitin slows progression and relieves symptoms of knee osteoarthritis

Jan 29, 2009

Osteoarthritis (OA) causes disability and is a major public health problem. A new study examined the effect of chondroitins 4 and 6 sulfate (CS) on OA progression and symptoms. CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries. The study was published in the February issue of Arthritis & Rheumatism.

Led by Andre Kahan of the University of Paris Descartes in Paris, the randomized, double-blind, placebo-controlled study involved 622 patients with OA from France, Belgium, Switzerland, Austria and the U.S. Patients had knee X-rays at the time of enrollment and at 12, 18 and 24 months. The X-rays were evaluated for joint space loss and patients were also assessed for OA symptoms and pain.

The results showed that "long-term administration of CS over 2 years can prevent joint structure degradation in patients with knee OA," the authors state. Joint space loss was significantly reduced in the CS group, fewer patients had progression of joint space width, and CS reduced pain in those taking it compared to the placebo group. CS was well-tolerated and there were no significant differences in the frequency of adverse events between the two groups.

The study showed that there was faster improvement regarding pain during the first year in the CS group compared to the placebo group. This may be due to the fact that all of the patients had pain symptoms, so the effect of CS was more noticeable early on. Since those who took a placebo also had decreased pain in the first year, it may also be due to the natural course of the disease. The authors note that the study involved CS, which is used as a prescription drug and that the results cannot be generalized to other chondroitin sulfate products or compounds, such as those available in the form of dietary supplements.

The decrease in joint space loss shown in this and another recent study involving 300 patients, suggests better outcomes for OA patients, according to the authors. They conclude: "Further studies with longer followup and different outcome criteria are warranted to assess whether the beneficial structural changes associated with CS demonstrated in our study are predictive of improvement in the long-term clinical progression of OA."

Journal: www3.interscience.wiley.com/journal/76509746/home

Source: Wiley

Explore further: Overwhelmed west Africa ramps up Ebola response

add to favorites email to friend print save as pdf

Related Stories

22 elephants poached in Mozambique in two weeks

25 minutes ago

Poachers slaughtered 22 elephants in Mozambique in the first two weeks of September, environmentalists said Monday, warning that killing for ivory by organised syndicates was being carried out on an "industrialised" ...

Recommended for you

Sierra Leone, Liberia brace for new Ebola cases

26 minutes ago

Two of the West African nations hardest hit by Ebola were bracing for new caseloads on Monday after trying to outflank the outbreak with a nationwide checkup and a large new clinic.

Reversing the effects of pulmonary fibrosis

49 minutes ago

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

Streets bustling after Sierra Leone shutdown ends

7 hours ago

Streets in Sierra Leone's capital bustled again Monday after an unprecedented nationwide shutdown during which officials said more than 1 million households were checked for Ebola patients and given information ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

VOR
not rated yet Jan 30, 2009
"CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries" .... I'm confused by the wording 'CS, unlike other chondroitin sufate products'... this implies it is different and unique, but I dont think thats what they mean to say.. very confusing! is it unique chemically or only unique in that its approved? anyone know? I think its the latter but its written so poorly I cant be sure.
VOR
not rated yet Feb 01, 2009
this helps clarify: http://www.nutrai...on-Study